Reframe vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W21 alcohol reduction app at $13M ARR with 150K+ paying customers; $17.4M Series B Goodwater 2022 with neuroscience-based CBT and community support competing with Monument for gray-area drinker digital behavior change.
About
Reframe (formerly Glucobit) is a San Francisco-based digital health platform — backed by Y Combinator (W21) — providing people seeking to quit or reduce alcohol consumption with a neuroscience-based mobile app that combines behavioral psychology, habit tracking, and community support, achieving $13 million in annual revenue with 150,000+ paying customers after 10x growth in 12 months and 3,000% growth in 6 months to become one of the top health apps on the App Store. Founded in 2018 by Ziyi Gao and Vedant Pradeep, Reframe raised $17.4 million in a Series B in January 2022 from Goodwater Capital, applying evidence-based alcohol reduction techniques (including CBT, mindfulness, and neuroscience education about alcohol's brain effects) to the 30 million Americans who want to drink less but don't seek traditional addiction treatment.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.